Wall Street rushed to India chasing one of the world’s fastest growing healthcare markets, only to run straight into the debate over who actually pays the bill.
According to data compiled by EY, Blackstone, KKR, TPG, General Atlantic and other global investors have poured about $10 billion into Indian hospital chains over the past five years.
The influx of capital has helped fund new facilities, expensive technology and a major hospital buyout in a county that still runs short on hospital beds. India has turned into one of the world’s most active markets for private-equity in healthcare, with funds zeroing in on big-money specialties like cardiac surgery and cancer care.
According to a report by The Economic Times, hospital groups in India have reported a significant growth in two key operational parameters:
An increase in average revenue per operating bed (ARPOB).
A decline in the average length of stay (ALOS) of patients.
Operational growth has helped chains boost their valuations on the stock exchange. For patients, these parameters have resulted in higher treatment costs, which is true even for relatively short hospital stays. Medical inflation in India was estimated at around 14% in 2021, which remains steep in post-pandemic times.
According to the Bloomberg article, approximately 1.3 hospital beds are available per 1,000 people in India, which is far below the levels in many developed countries. Demand for cancer care, cardiac treatment and other specialized services is rising as incomes expand and life expectancy improves.
Global investors have identified an industry requiring heavy upfront investment but suitable for generating long-term cash flows as well as a fragmented landscape of standalone hospitals that could be consolidated into national chains with broader specialist offerings and higher returns on investment.
Policymakers identified approximately 600 hospital projects requiring roughly $32 billion in investment in 2021, emphasizing both the shortage of healthcare infrastructure and the scale of the opportunity.
Also Read : More Orthopedic Physicians Sell Out to Private Equity Firms, Raising Alarms About Costs and Quality
Blackstone, KKR, TPG, General Atlantic and other international investors have helped expand and strengthen India’s healthcare market by providing hospital groups across the country with funding for new acquisitions, facilities, and technology.
While fewer than 5% of the country’s hospital beds are private equity-backed, these investors have established significant positions in profitable areas including oncology and cardiac care.
KKR previously backed Radiant Life Care and its subsequent merger with the listed Max Healthcare institute; its exit in 2022 from Max generated substantial returns.
Temasek has generated an estimated tenfold return on its investment in Manipal Health Enterprises after a partial sale linked to the hospital operator’s planned IPO.
According to VCCirlce, an Indian private-market data provider, the investment produced an annualized internal rate of return of approximately 30%.
Other investors have also benefited from India’s increasingly liquid capital markets, which have provided opportunities to exit investments through stock-market listings and secondary transactions. The strong performance of the sector has led to further investments.
Crisil expects private hospital revenues to increase by up to 15% in fiscal 2027, driven by a higher number of patients and an increase in revenue generated per occupied bed.
Concerns are growing that the rapid expansion of private equity may be increasing healthcare costs and restricting patients’ access to care.
Much of this criticism arises from escalating tension between the hospitals and insurers. Insurers allege that private providers, including those at PE-backed chains, are overcharging and pushing patients towards high-cost procedures. While, hospital operators claim that delayed insurance payments and inadequate reimbursement rates are squeezing operating margins.
The debate has also focused on what care should be covered. As hospitals adopt more advanced and costly treatments, insurers are questioning whether these procedures provide a sufficient clinical benefit to justify their expense. Hospitals argue that newer technologies, implants and surgical techniques improve outcomes despite higher initial costs.
Despite the sector’s strong financial performance, it is facing intense regulatory scrutiny over patient affordability.
The 80th round of the National Sample Survey, covering January to December 2025, found that the average cost of hospitalization was ₹6,631 in government hospitals compared with ₹50,508 in private hospitals.
The Parliamentary Standing Committee on Health and Family Welfare noted that private hospital treatment can be five to 10 times more expensive than treatment in government facilities, highlighting the scale of the affordability gap.
In August, a parliamentary committee tasked with examining the economic fallout of India’s private hospital boom, warned that an “unchecked influx of foreign capital” was fueling the buyout of cost effective, mid-size hospitals by large private equity groups.
The committee also recommended that room charges in private hospitals in large metropolitan cities should not exceed the average room tariffs of three-star hotels in the peripheral area or vicinity of the hospital. It said costs such as resident doctors, nursing, consumables, meals and laundry could be added to the basic room tariff.
To counter this trend, the panel pushed to rethink of foreign investment rules in healthcare, calling for price caps on medical treatments and the creation of a dedicated hospital regulator. All this comes as medical inflation has climbed up by 13% annually, according to the report.
(Rh/APC/MSM)